<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJFNS</journal-id><journal-title-group><journal-title>Hans Journal of Food and Nutrition Science</journal-title></journal-title-group><issn pub-type="epub">2166-613X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJFNS.2020.94037</article-id><article-id pub-id-type="publisher-id">HJFNS-38522</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJFNS20200400000_41341653.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  左旋肉碱补充剂对超重与肥胖人群血脂水平影响的Meta分析
   The Effects of L-CarnitineSupplementation on the Lipid Profiles in Over-weight or Obesity Population: A Meta-Analysis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>艳莹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>静娴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>冰蟾</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>求</surname><given-names>越</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>贤荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>杭州师范大学医学院预防医学系，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>16</day><month>09</month><year>2020</year></pub-date><volume>09</volume><issue>04</issue><fpage>276</fpage><lpage>287</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：评价左旋肉碱补充剂对超重与肥胖人群血脂水平的作用。方法：通过系统检索中国知网(CNKI)、万方数据知识服务平台、维普网、PubMed、ScienceDirect等数据库，检索时间从建库至2020年6月。根据Cochrane系统评价方法，筛选采用左旋肉碱(试验组)对比安慰剂(对照组)治疗超重、肥胖患者的随机对照试验(RCT)，进行纳入文献的资料提取和质量评价，采用Rev Man 5.3软件进行Meta分析。比较试验组与对照组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、体脂率(BF%)、体重、体质指数(BMI)、腰臀比(WHR)等指标。结果：共纳入8篇符合标准的随机对照试验。Meta分析结果显示，试验组TC水平(SMD = 0.23, 95%CI[0.03,0.43], P
    = 0.02)、TG水平(SMD = 0.21, 95%CI[0.01,0.41], 
   P
    = 0.04)、LDL水平(SMD = 0.32,95%CI[0.08, 0.56], 
   P
    = 0.008)、BMI水平(MD = 1.01, 95%CI[0.27,1.74], 
   P
    = 0.007)、WHR水平(MD = 0.02,95%CI[0.00, 0.04], 
   P
    = 0.02)降低程度大于对照组；两组在HDL水平升高程度(SMD = 0.20, 95%CI[−0.04, 0.43], 
   P
    = 0.10)、体重和BF%降低程度(体重：MD = 1.26, 95%CI[−1.36, 3.87], 
   P
    = 0.35；BF%: MD = 2.51, 95%CI[−0.16, 5.17], 
   P
    = 0.07)的差异无统计学意义。结论：左旋肉碱补充剂显著改善超重、肥胖人群的TC、TG、LDL水平。
    Objective: To evaluate the effects of L-carnitine supplementation on lipid profile in overweight and obesity population. Methods: A comprehensive systematic literature search in the electronic databases, including CNKI, Wanfang, VIP, Pub Med, Science Direct, were carried out upto June, 2020. According to the standard procedures of The Cochrane Collaboration, randomized control trials that use L-carnitine supplementation (experiment group) and placebo in overweight and obesity population were selected. Data were extracted and quality was assessed, and the meta-analysis was conducted using Rev Man 5.3 software. The parameters, including total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), body fat rate (BF%), body weight, body mass index (BMI), and waist-hip ratio (WHR), were analyzed and compared between experiment and control group. Results: 8 RCTs of adequate methodological quality were included in the study. Results from meta-analysis of eligible trials revealed that subjects in experiment group had significant greater declines in TC (SMD = 0.23, 95%CI: 0.03, 0.43, 
   P
    = 0.02), TG (SMD = 0.21, 95%CI: 0.01, 0.41, 
   P
    = 0.04), LDL-C (SMD = 0.32, 95%CI: 0.08, 0.56, 
   P
    = 0.008), BMI (MD = 1.01, 95%CI: 0.27, 1.74, 
   P
    = 0.007) and WHR (MD = 0.02, 95%CI: 0.00, 0.04, 
   P
    = 0.02) than those of the subjects in control group. There were no significant differences in the changes of HDL-C, body weight (MD = 1.26, 95%CI: −1.36, 3.87, 
   P
    = 0.35) and BF% (MD = 2.51, 95%CI: −0.16, 5.17, 
   P
    = 0.07) among the subjects in these two groups. Conclusion: L-carnitine supplement could result in significant improvement inTC, TG and LDL-C level in overweigh and obesity populations. 
  
 
</p></abstract><kwd-group><kwd>左旋肉碱，超重，肥胖，血脂，Meta分析,  L-Carnitine</kwd><kwd> Overweight</kwd><kwd> Obesity</kwd><kwd> Blood Lipid</kwd><kwd> Me-ta-Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价左旋肉碱补充剂对超重与肥胖人群血脂水平的作用。方法：通过系统检索中国知网(CNKI)、万方数据知识服务平台、维普网、PubMed、ScienceDirect等数据库，检索时间从建库至2020年6月。根据Cochrane系统评价方法，筛选采用左旋肉碱(试验组)对比安慰剂(对照组)治疗超重、肥胖患者的随机对照试验(RCT)，进行纳入文献的资料提取和质量评价，采用Rev Man 5.3软件进行Meta分析。比较试验组与对照组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、体脂率(BF%)、体重、体质指数(BMI)、腰臀比(WHR)等指标。结果：共纳入8篇符合标准的随机对照试验。Meta分析结果显示，试验组TC水平(SMD = 0.23, 95%CI[0.03,0.43], P = 0.02)、TG水平(SMD = 0.21, 95%CI[0.01,0.41], P = 0.04)、LDL水平(SMD = 0.32,95%CI[0.08, 0.56], P = 0.008)、BMI水平(MD = 1.01, 95%CI[0.27,1.74], P = 0.007)、WHR水平(MD = 0.02,95%CI[0.00, 0.04], P = 0.02)降低程度大于对照组；两组在HDL水平升高程度(SMD = 0.20, 95%CI[−0.04, 0.43], P = 0.10)、体重和BF%降低程度(体重：MD = 1.26, 95%CI[−1.36, 3.87], P = 0.35；BF%: MD = 2.51, 95%CI[−0.16, 5.17], P = 0.07)的差异无统计学意义。结论：左旋肉碱补充剂显著改善超重、肥胖人群的TC、TG、LDL水平。</p></sec><sec id="s2"><title>关键词</title><p>左旋肉碱，超重，肥胖，血脂，Meta分析</p></sec><sec id="s3"><title>The Effects of L-Carnitine Supplementation on the Lipid Profiles in Overweight or Obesity Population: A Meta-Analysis</title><p>Yanying Lu, Jingxian Wang, Bingchan Zhu, Yue Qiu, Xianrong Xu<sup>*</sup></p><p>Department of Preventive Medicine, School of Medicine, Hangzhou Normal University, Hangzhou Zhejiang</p><p><img src="//html.hanspub.org/file/3-1740427x5_hanspub.png" /></p><p>Received: Oct. 16<sup>th</sup>, 2020; accepted: Oct. 30<sup>th</sup>, 2020; published: Nov. 6<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/3-1740427x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the effects of L-carnitine supplementation on lipid profile in overweight and obesity population. Methods: A comprehensive systematic literature search in the electronic databases, including CNKI, Wanfang, VIP, Pub Med, Science Direct, were carried out upto June, 2020. According to the standard procedures of The Cochrane Collaboration, randomized control trials that use L-carnitine supplementation (experiment group) and placebo in overweight and obesity population were selected. Data were extracted and quality was assessed, and the meta-analysis was conducted using Rev Man 5.3 software. The parameters, including total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), body fat rate (BF%), body weight, body mass index (BMI), and waist-hip ratio (WHR), were analyzed and compared between experiment and control group. Results: 8 RCTs of adequate methodological quality were included in the study. Results from meta-analysis of eligible trials revealed that subjects in experiment group had significant greater declines in TC (SMD = 0.23, 95%CI: 0.03, 0.43, P = 0.02), TG (SMD = 0.21, 95%CI: 0.01, 0.41, P = 0.04), LDL-C (SMD = 0.32, 95%CI: 0.08, 0.56, P = 0.008), BMI (MD = 1.01, 95%CI: 0.27, 1.74, P = 0.007) and WHR (MD = 0.02, 95%CI: 0.00, 0.04, P = 0.02) than those of the subjects in control group. There were no significant differences in the changes of HDL-C, body weight (MD = 1.26, 95%CI: −1.36, 3.87, P = 0.35) and BF% (MD = 2.51, 95%CI: −0.16, 5.17, P = 0.07) among the subjects in these two groups. Conclusion: L-carnitine supplement could result in significant improvement inTC, TG and LDL-C level in overweigh and obesity populations.</p><p>Keywords:L-Carnitine, Overweight, Obesity, Blood Lipid, Meta-Analysis</p><disp-formula id="hanspub.38522-formula7"><graphic xlink:href="//html.hanspub.org/file/3-1740427x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1740427x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1740427x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>超重和肥胖是全球范围内面临的重大公共卫生问题，已经成为多种疾病的重要危险因素，包括2型糖尿病，心血管疾病，高血压、脑卒中以及多种癌症 [<xref ref-type="bibr" rid="hanspub.38522-ref1">1</xref>]。在我国，随着社会经济的发展，居民膳食能量供给日益充足，在各人群中超重肥胖率均出现显著上升趋势。研究显示，从1991年到2015年，我国儿童和青少年中超重和肥胖率分别由5%和1.7%增加到11.7%和6.8% [<xref ref-type="bibr" rid="hanspub.38522-ref2">2</xref>]。《中国居民营养与慢性病状况报告(2015年)》 [<xref ref-type="bibr" rid="hanspub.38522-ref3">3</xref>] 中指出，按照中国标准，2012年18岁及以上成年超重率为30.1%，肥胖率为11.9%。超重和肥胖可导致血脂代谢紊乱，诱发血糖代谢异常和动脉粥样硬化，增加心血管疾病和糖尿病风险 [<xref ref-type="bibr" rid="hanspub.38522-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref5">5</xref>]。因此，在我国人群中降低超重和肥胖发生率，改善人群血脂水平，对于慢性病防控具有重要的意义。</p><p>左旋肉碱(L-carnitine)，别称k肉毒碱、维生素BT或左卡尼汀，是一种具有多种生理功能的化合物 [<xref ref-type="bibr" rid="hanspub.38522-ref6">6</xref>]。研究显示，左旋肉碱对肥胖、糖尿病、神经退行性疾病等多种类型疾病具有重要作用 [<xref ref-type="bibr" rid="hanspub.38522-ref7">7</xref>]。此外，左旋肉碱还参与脂质代谢过程，能够携带脂肪酸进入线粒体实现β-氧化过程，进而发挥调控血脂的作用 [<xref ref-type="bibr" rid="hanspub.38522-ref8">8</xref>]。近年来，以左旋肉碱为主要成分的减肥健身食品或非处方药(OTC)很受欢迎，且已有多项研究表明左旋肉碱具有减肥作用 [<xref ref-type="bibr" rid="hanspub.38522-ref9">9</xref>]。然而，其对于改善超重或肥胖人群血脂水平的结论不一。因此，本研究将采用Meta分析的方法，通过数据库检索左旋肉碱干预肥胖或超重人群的随机对照试验文献，按照Cochrane系统评价流程，阐明左旋肉碱干预对超重肥胖患者血脂水平的影响，为其在临床上的进一步应用提供参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 文献纳入与排除标准</title><p>文献纳入标准：1) 研究对象：超重和肥胖患者，即BMI大于24.0 kg/m<sup>2</sup>，符合中国超重和肥胖的诊断标准 [<xref ref-type="bibr" rid="hanspub.38522-ref10">10</xref>]；受试对象年龄大于等于18周岁，性别、种族等不限；2) 干预措施：口服左旋肉碱，不进行饮食控制，可同时配合运动，治疗期间服用剂量不变，疗程大于等于4周；3) 对照措施：口服安慰剂不进行饮食控制，可同时配合运动，治疗期间服用剂量不变，疗程大于等于4周；4) 结局指标：主要结局指标为血脂四项：总胆固醇(TC)、甘油三酯(TG)、HDL(高密度脂蛋白)、LDL(低密度脂蛋白)。次要结局指标：体脂率(BF%)、体重、体质指数(BMI)、腰臀比(WHR)。连续性变量的结局指标均包括治疗前后水平的平均值和标准差，结局指标的测量时间为治疗开始和结束时；5) 研究类型：随机对照试验(RCT)，无论文献发表与否、是否采用分配隐藏及盲法；研究文献为全文文献；语种不限；时间从建库起至2020年6月。</p><p>文献排除标准：1) 动物实验；2) 研究设计为无对照的、自身交叉对照的临床试验等非RCT；3) 研究对象合并糖尿病、脂肪肝等代谢疾病，以及其他心、肝、肾和造血系统等严重疾病；4) 研究对象为运动员等人群的非减重研究；5) 在治疗期前6个月进行过减肥相关事宜；6) 左旋肉碱合并其他药物的减肥研究；7) 无法获取全文、数据不全或者无本次分析需要的相关结局指标。</p></sec><sec id="s6_2"><title>2.2. 文献检索策略</title><p>计算机检索Pubmed、Science direct、中国知网(CNKI)、维普、万方数据知识服务平台等数据库，检索时间从建库至2020年6月。同时从相关综述、系统分析中追查相关纳入文献及其参考文献。中文检索词9个，包括L-肉碱、左旋肉碱、超重、肥胖、血脂等，具体检索式为：SU = 左旋肉碱 OR TKA = 左旋肉碱 AND (SU = 超重 OR TKA = 超重 OR SU = 肥胖 OR TKA = 肥胖) AND (SU = 血脂 OR TKA = 血脂)；英文检索词5个，包括Lipid、Hyperlipidemias、obesity、overweight、L-carnitine等，具体检索式为：((((“Carnitine”[Mesh]) OR (L-Carnitine[Title/Abstract])) OR (L-Carnitine[Title])) AND ((((“Overweight”[Mesh]) OR (overweight[Title/Abstract])) OR (overweight[Title])) OR (((“Obesity”[Mesh]) OR (obesity[Title/Abstract])) OR (obesity[Title])))) AND ((((“Hyperlipidemias”[Mesh]) OR“Lipids”[Mesh]) OR (Hyperlipidemias[Title/Abstract])) OR (Hyperlipidemias[Title]))。</p></sec><sec id="s6_3"><title>2.3. 资料提取</title><p>根据事先设计的表格，由2名评价员独立进行，若存在争议则通过第三方仲裁及讨论解决。通过阅读全文，采用自行设计的资料提取表摘录各研究相关信息，包括标题、作者、发表日期、样本量、研究设计类型、研究对象基本特征、具体干预措施、疗程、偏倚的控制措施(随机分组、盲法、分组隐藏等)、研究期间失访情况及原因说明、主要和次要结局指标等。对于研究中涉及多个分组情况，则仅提取本研究相关分组与结果。纳入研究的结局指标单位换算统一，即TC、HDL、LDL计量单位1 mmol/l = 38.7 mg/dl，TG计量单位1 mmol/l = 88.6 mg/dl。在进行Meta分析时，对于每项临床研究，必须有治疗效应(即治疗前后测量指标差值的均数)及其标准差，研究未给出连续性变量差值的均数(见公式1)和标准差(见公式2)，则使用下列公式 [<xref ref-type="bibr" rid="hanspub.38522-ref11">11</xref>] 进行换算：公式1： d 1 = X 11 − X 12 ；公式2： S 1 = s 11 2 + s 12 2 － 2 s 11 &#215; s 12 &#215; 0.4 。 d 为治疗效应，即差值的均数； X 11 为治疗前的平均值； X 12 为治疗后的平均值； S 为差值的标准差； S 11 为治疗前的标准差； S 12 为治疗后的标准差。</p></sec><sec id="s6_4"><title>2.4. 偏倚风险评价</title><p>由2名评价员分别采用Cochrane协作网推荐的偏倚风险评价工具进行评价 [<xref ref-type="bibr" rid="hanspub.38522-ref12">12</xref>]，包括6个方面：1) 随机分配方法是否正确；2) 分配方案隐藏是否完善；3) 是否采用盲法；4) 结果数据是否完整；5) 是否有选择性报告研究结果；6) 有无其他来源的偏倚。每条标准按照“低风险”“高风险”“不清楚”来划分。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>根据Cochrane系统评价手册 [<xref ref-type="bibr" rid="hanspub.38522-ref13">13</xref>]，先将各项研究中的数据进行合并，然后采用Cochrane协作网提供的Rev Man 5.3统计软件进行统计学分析。采用I<sup>2</sup>检验对纳入文献进行统计学异质性分析，当P ≥ 0.1和I<sup>2</sup> ≤ 50%时，表示各研究间无统计学异质性，则采用固定效应模型；若P &lt; 0. 1和I<sup>2</sup>&gt; 50%，表示各研究间存在统计学异质性，则对异质性来源进行分析，通过亚组及敏感性分析等处理减小异质性后，再采用固定效应模型进行Meta分析，若异质性仍较大，则采用随机效应模型进行分析。连续性变量用均数差(MD)表示，区间估计均采用95%可信区间(95% CI)，以P &lt;0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 文献检索</title><p>检索出相关文献共443篇，其中中文171篇，英文272篇。去除重复文献后为213篇，阅读题目及摘要后剩下62篇，经阅读全文排除不符合纳入标准的54篇，最终纳入符合要求的文献8篇 [<xref ref-type="bibr" rid="hanspub.38522-ref13">13</xref>] - [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>]，其中英文2篇，英文6篇，共包括390超重及肥胖患者，其中试验组193人，对照组197人。文献筛选流程见图1，纳入文献的基本特征见表1。</p><p>图1. 文献筛选流程图</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Basic characteristics of the included studie</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >第一作者</th><th align="center" valign="middle"  rowspan="2"  >发表年限(年)</th><th align="center" valign="middle"  colspan="2"  >例数</th><th align="center" valign="middle"  rowspan="2"  >随访时间(周)</th><th align="center" valign="middle"  colspan="2"  >干预措施</th><th align="center" valign="middle"  rowspan="2"  >结局指标</th></tr></thead><tr><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >对照组</td></tr><tr><td align="center" valign="middle" >甄静</td><td align="center" valign="middle" >2014</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >①②③④⑤⑥⑦⑧</td></tr><tr><td align="center" valign="middle" >胡飞燕</td><td align="center" valign="middle" >2008</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >①②③④⑤⑥⑦⑧</td></tr><tr><td align="center" valign="middle" >黄宗锈</td><td align="center" valign="middle" >2007</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6粒胶囊(剂量不明)</td><td align="center" valign="middle" >6粒胶囊(剂量不明)</td><td align="center" valign="middle" >①②⑤⑦⑧</td></tr><tr><td align="center" valign="middle" >王自力</td><td align="center" valign="middle" >2014</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2 g/d</td><td align="center" valign="middle" >−</td><td align="center" valign="middle" >①②③④</td></tr><tr><td align="center" valign="middle" >杨延平</td><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1.5 g/d，结合运动</td><td align="center" valign="middle" >1.5 g/d，结合运动</td><td align="center" valign="middle" >①②③④⑤⑥⑦⑧</td></tr><tr><td align="center" valign="middle" >周斅激</td><td align="center" valign="middle" >2004</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >2 g/d，结合运动</td><td align="center" valign="middle" >①②③④⑤⑥⑦⑧</td></tr><tr><td align="center" valign="middle" >Mahdavi</td><td align="center" valign="middle" >2015</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0.75 g/d</td><td align="center" valign="middle" >0.75 g/d</td><td align="center" valign="middle" >①②③④⑤⑥</td></tr><tr><td align="center" valign="middle" >Samimi</td><td align="center" valign="middle" >2016</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >0.25 g/d</td><td align="center" valign="middle" >0.25 g/d</td><td align="center" valign="middle" >①②③④⑤⑥</td></tr></tbody></table></table-wrap><p>表1. 纳入研究的基本特征</p><p>注：① 为体重；② 为体质指数(BMI)，BMI单位是kg/m<sup>2</sup>；③ 为血浆总胆固醇(TC)；④ 为甘油三酯(TG)；⑤ 为高密度脂蛋白(HDL)；⑥ 为低密度脂蛋白(LDL)；⑦ 为体脂率(BF%)；⑧ 为腰臀比(WHR)。</p></sec><sec id="s7_2"><title>3.2. 纳入研究的偏倚风险评估</title><p>纳入文献均说明为“随机分配”，但仅有3篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref20">20</xref>] 描述了随机分配具体操作过程，如计算机随机数字法；关于盲法，1篇单盲 [<xref ref-type="bibr" rid="hanspub.38522-ref13">13</xref>]、1篇 [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>] 双盲，余均提及盲法但未具体描述盲法的实施；在数据及报告方面，8篇纳入文献均完整详细，具体见图2、图3。</p><p>图2. 纳入文献的偏倚风险评价</p><p>图3. 每项纳入文献的偏倚风险</p></sec><sec id="s7_3"><title>3.3. Meta分析结果</title><sec id="s7_3_1"><title>3.3.1. 总胆固醇(TC)</title><p>8篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] - [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了总胆固醇水平，各研究间无统计学异质性(P = 0.25, I<sup>2</sup> = 22%)，采用固定效应模型。Meta分析结果显示，试验组TC水平降低程度大于对照组，差异有统计学意义(SMD = 0.23, 95%CI[0.03, 0.43], P = 0.02，见图4)。</p><p>图4. TC水平改变比较的森林图</p></sec><sec id="s7_3_2"><title>3.3.2. 甘油三酯(TG)</title><p>8篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] - [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象甘油三酯的变化，各研究间不存在统计学异质性(P = 0.55, I<sup>2</sup> = 0%)，采用固定效应模型。Meta分析结果显示，试验组TG水平降低程度高于对照组，差异有统计学意义(SMD = 0.21, 95%CI[0.01, 0.41], P = 0.04，见图5)。</p><p>图5. TG水平改变比较的森林图</p></sec><sec id="s7_3_3"><title>3.3.3. 高密度脂蛋白(HDL)</title><p>7篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后高密度脂蛋白水平的变化，各研究间不存在统计学异质性(P = 0.22, I<sup>2</sup> = 27%)，采用固定效应模型。Meta分析结果显示，试验组HDL水平升高程度与对照组相比，差异无统计学意义(SMD = 0.20, 95%CI[−0.04, 0.43], P = 0.10，见图6)。</p><p>图6. HDL-C水平改变比较的森林图</p></sec><sec id="s7_3_4"><title>3.3.4. 低密度脂蛋白胆固醇(LDL-C)</title><p>7篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象低密度脂蛋白的变化，各研究间不存在统计学异质性(P = 0.13, I<sup>2</sup> = 40%)，采用固定效应模型。Meta分析结果显示，试验组LDL水平降低程度高于对照组，差异有统计学意义(SMD = 0.32, 95%CI[0.08, 0.56], P = 0.008，见图7)。</p></sec><sec id="s7_3_5"><title>3.3.5 体重及体质指数(BMI)</title><p>7篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] - [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象体重的变化，各研究间不存在统计学异质性(P = 0.99, I<sup>2</sup> = 0%)，采用固定效应模型。Meta分析结果显示，试验组与对照组体重水平降低程度的差异无统计学意义(MD = 1.26, 95%CI[−1.36, 3.87], P = 0.35，见图8)。</p><p>图7. LDL-C水平改变比较的森林图</p><p>图8. 体重改变比较的森林图</p><p>6篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象体质指数的变化，各研究间不存在统计学异质性(P = 0.88, I<sup>2</sup> = 0%)，采用固定效应模型。Meta分析结果显示，试验组BMI水平降低程度高于对照组，差异有统计学意义(MD = 1.01, 95%CI[0.27, 1.74], P = 0.007，见图9)。</p><p>图9. BMI水平改变比较的森林图</p></sec><sec id="s7_3_6"><title>3.3.6. 体脂率及腰臀比</title><p>5篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象体脂率的变化，各研究间不存在统计学异质性(P = 0.98, I<sup>2</sup> = 0% )，采用固定效应模型。Meta分析结果显示，试验组BF%降低程度对于对照组，差异无统计学意义(MD = 2.51, 95%CI[−0.16, 5.17], P = 0.07，见图10)。</p><p>4篇文献 [<xref ref-type="bibr" rid="hanspub.38522-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 报道了治疗前后研究对象腰臀比的变化，各研究间不存在统计学异质性(P = 0.19, I<sup>2</sup> = 37% )，采用固定效应模型。Meta分析结果显示，试验组WHR水平降低程度高于对照组，差异有统计学意义(MD = 0.02, 95%CI: 0.00, 0.04, P = 0.02) (见图11)。</p><p>图10. 体脂率水平改变比较的森林图</p><p>图11. 腰臀比水平改变比较的森林图</p></sec></sec><sec id="s7_4"><title>3.4. 偏倚分析</title><p>分别对报道了血浆总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)水平的文献绘制漏斗图(见图12~15)。结果显示，图12、图14、图15中的散点集中分布在无效线两侧，漏斗图基本对称，但图13中的部分散点未处于95% CI线之间或位于无效线中轴上，且图14中的散点呈不对称分布，提示根据TC、TG、HDL、LDL纳入的文献存在一定程度发表偏倚。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>随着经济水平提高，居民膳食结构也发生较大变化，与此同时也出现了数量众多的超重、肥胖人群，并呈现不断增长的趋势 [<xref ref-type="bibr" rid="hanspub.38522-ref22">22</xref>]。超重和肥胖人群容易伴发血脂异常，两者均为心血管疾病的重要危险因素，且存在交互作用。在肥胖人群中，在血脂正常的情况下，体重增长并不会增加心血管疾病和糖尿病的风险，提示在肥胖人群中控制血脂的重要性 [<xref ref-type="bibr" rid="hanspub.38522-ref23">23</xref>]。</p><p>图12. TG发表偏倚的漏斗图</p><p>图13. TC发表偏倚的漏斗图</p><p>图14. HDL-C发表偏倚的漏斗图</p><p>图15. LDL-C发表偏倚的漏斗图</p><p>本研究结果表明，在超重和肥胖人群中，采用左旋肉碱干预除了能够降低体质指数，腰臀比的同时，可有效降低TG、TC、以及LDL-C水平，提示左旋肉碱具有降低血脂，保护心血管功能的作用。在肉碱缺乏的患者中，补充左旋肉碱可增加运动过程中骨骼肌对脂肪酸的氧化速度，从而发挥保护心血管功能的作用 [<xref ref-type="bibr" rid="hanspub.38522-ref24">24</xref>]。Askarpour等研究发现，左旋肉碱可有效降低TC，TG，LDL-C水平，升高HDL-C，但其结果与应用的剂量有关，且在接受透析治疗的病人中没有这种效果 [<xref ref-type="bibr" rid="hanspub.38522-ref25">25</xref>]。动物研究表明，左旋肉碱可通过增加骨骼肌中PPAR-γ和葡萄糖受体的表达，从而发挥降低炎症水平和调控血脂的作用 [<xref ref-type="bibr" rid="hanspub.38522-ref26">26</xref>]。这些研究均支持了左旋肉碱在减肥的同时具有调控血脂的作用。</p><p>本研究依然存在一些问题。首先，纳入文献对随机分配和盲法实施过程未加以详细说明，文献质量方面有3篇 [<xref ref-type="bibr" rid="hanspub.38522-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.38522-ref21">21</xref>] 属于低质量，存在一定偏倚风险。在评价发表偏倚时也发现纳入文献存在一定程度发表偏倚，同时纳入文献数量较少。因此，尚需对更多国内外高质量的RCT进行评价，以进一步验证本研究结果。</p></sec><sec id="s9"><title>基金项目</title><p>本研究得到杭州师范大学医学院教改项目(项目编号：YXYJG2020012)，浙江省自然科学基金(项目编号为LQ15H260002)、国家自然科学基金(项目编号为81602795)资助。</p></sec><sec id="s10"><title>文章引用</title><p>卢艳莹,王静娴,朱冰蟾,求 越,徐贤荣. 左旋肉碱补充剂对超重与肥胖人群血脂水平影响的Meta分析 The Effects of L-CarnitineSupplementation on the Lipid Profiles in Over-weight or Obesity Population: A Meta-Analysis[J]. 食品与营养科学, 2020, 09(04): 276-287. https://doi.org/10.12677/HJFNS.2020.94037</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38522-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Williams, E.P., Mesidor, M., Winters, K., et al. (2015) Overweight and Obesity: Prevalence, Consequences, and Causes of a Growing Public Health Problem. Current Obesity Reports, 4, 363-370.  
&lt;br&gt;https://doi.org/10.1007/s13679-015-0169-4</mixed-citation></ref><ref id="hanspub.38522-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Yin, X., Wu, H., et al. (2019) Trends in Overweight and Obesity among Children and Adolescents in China from 1991 to 2015: A Meta-Analysis. International Journal of Envi-ronmental Research and Public Health, 16, 4656.  
&lt;br&gt;https://doi.org/10.3390/ijerph16234656</mixed-citation></ref><ref id="hanspub.38522-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">顾景范. 《中国居民营养与慢性病状况报告(2015)》解读[J]. 营养学报, 2016, 38(6): 525-529.</mixed-citation></ref><ref id="hanspub.38522-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nishide, R., Ando, M., Funabashi, H., et al. (2015) Association of Serum hs-CRP and Lipids with Obesity in School Children in a 12-Month Follow-Up Study in Japan. Environmental Health and Pre-ventive Medicine, 20, 116-122.  
&lt;br&gt;https://doi.org/10.1007/s12199-014-0433-3</mixed-citation></ref><ref id="hanspub.38522-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sindelka, G., Skrha, J., Prazny, M., et al. (2002) Association of Obesity, Diabetes, Serum Lipids and Blood Pressure Regulates Insulin Action. Physiological Research, 51, 85-91.</mixed-citation></ref><ref id="hanspub.38522-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Jacques, F., Rippa, S. and Perrin, Y. (2018) Physiology of L-carnitine in Plants in Light of the Knowledge in Animals and Microorganisms. Plant Science, 274, 432-440. &lt;br&gt;https://doi.org/10.1016/j.plantsci.2018.06.020</mixed-citation></ref><ref id="hanspub.38522-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cha, Y.S. (2008) Effects of L-carnitine on Obesity, Diabetes, and as an Ergogenic Aid. Asia Pacific Journal of Clinical Nutrition, 17, 306-308.</mixed-citation></ref><ref id="hanspub.38522-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Muller, D.M., Seim, H., Kiess, W., et al. (2002) Effects of Oral L-carnitine Supplementation on in Vivo Long-Chain Fatty Acid Oxidation in Healthy Adults. Metabolism, 51, 1389-1391. &lt;br&gt;https://doi.org/10.1053/meta.2002.35181</mixed-citation></ref><ref id="hanspub.38522-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Pooyandjoo, M., Nouhi, M., Shab-Bidar, S., et al. (2016) The Effect of (L-)carnitine on Weight Loss in Adults: A Systematic Review and Me-ta-Analysis of Randomized Controlled Trials. Obesity Reviews, 17, 970-976.  
&lt;br&gt;https://doi.org/10.1111/obr.12436</mixed-citation></ref><ref id="hanspub.38522-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">葛均波, 徐永健. 内科学[M]. 北京: 人民卫生出版社, 2013: 733-771.</mixed-citation></ref><ref id="hanspub.38522-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">郭丽敏, 林珊珊. 阿卡波糖与二甲双胍治疗糖尿病前期疗效的Meta分析[J]. 临床医药文献电子杂志, 2018, 5(95): 163.</mixed-citation></ref><ref id="hanspub.38522-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. (2011) The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ, 343, d5928. &lt;br&gt;https://doi.org/10.1136/bmj.d5928</mixed-citation></ref><ref id="hanspub.38522-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cumpston, M., Li, T., Page, M.J., et al. (2019) Updated Guidance for Trusted Systematic Reviews: A New Edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews, 10, ED000142. &lt;br&gt;https://doi.org/10.1002/14651858.ED000142</mixed-citation></ref><ref id="hanspub.38522-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">甄静. 补充左旋肉碱结合运动对体重正常和超重大学生脂代谢及最大摄氧量的影响[D]: [硕士学位论文]. 南京: 南京体育学院, 2014.</mixed-citation></ref><ref id="hanspub.38522-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王自力. 左卡尼汀对肥胖骨质疏松椎体压缩骨折患者术后恢复及脂代谢影响[J]. 中国骨质疏松杂志, 2014, 20(5): 542-546.</mixed-citation></ref><ref id="hanspub.38522-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">胡飞燕. 左旋肉碱配合有氧健身运动对肥胖女性的影响[J]. 江苏教育学院学报(自然科学版), 2008, 25(3): 37-39.</mixed-citation></ref><ref id="hanspub.38522-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">黄宗锈, 林健, 林春芳. 左旋肉碱对肥胖人员减肥作用的效果观察[J]. 预防医学论坛, 2007, 13(1): 6-8.</mixed-citation></ref><ref id="hanspub.38522-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">周斅激. L-肉碱配合有氧运动对肥胖女性脂肪代谢的影响[J]. 天津体育学院学报, 2004(4): 60-62.</mixed-citation></ref><ref id="hanspub.38522-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Malek Mahdavi, A., Mahdavi, R., Kolahi, S., et al. (2015) L-Carnitine Supple-mentation Improved Clinical Status without Changing Oxidative Stress and Lipid Profile in Women with Knee Osteoar-thritis. Nutrition Research, 35, 707-715. &lt;br&gt;https://doi.org/10.1016/j.nutres.2015.06.003</mixed-citation></ref><ref id="hanspub.38522-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Samimi, M., Jamilian, M., Ebrahimi, F.A., et al. (2016) Oral Carnitine Supplementation Reduces Body Weight and Insulin Resistance in Wom-en with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Endocrinology (Oxf), 84, 851-857. &lt;br&gt;https://doi.org/10.1111/cen.13003</mixed-citation></ref><ref id="hanspub.38522-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">杨延平. 运动结合减肥营养品对超重、肥胖女大学生脂代谢和炎症因子的影响[D]: [硕士学位论文]. 北京: 北京体育大学, 2018.</mixed-citation></ref><ref id="hanspub.38522-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bluher, M. (2019) Obesity: Global Epidemiology and Pathogenesis. Nature Reviews Endocrinology, 15, 288-298.  
&lt;br&gt;https://doi.org/10.1038/s41574-019-0176-8</mixed-citation></ref><ref id="hanspub.38522-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Fabbrini, E., Yoshino, J., Yoshino, M., et al. (2015) Metabolically Normal Obese People Are Protected from Adverse Effects Following Weight Gain. Journal of Clinical Investigation, 125, 787-795. &lt;br&gt;https://doi.org/10.1172/JCI78425</mixed-citation></ref><ref id="hanspub.38522-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Madsen, K.L., Preisler, N., Rasmussen, J., et al. (2018) L-Carnitine Improves Skeletal Muscle Fat Oxidation in Primary Carnitine Deficiency. The Journal of Clinical Endocri-nology and Metabolism, 103, 4580-4588.  
&lt;br&gt;https://doi.org/10.1210/jc.2018-00953</mixed-citation></ref><ref id="hanspub.38522-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Askarpour, M., Hadi, A., Symonds, M.E., et al. (2019) Efficacy of L-Carnitine Supplementation for Management of Blood Lipids: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrition, Metabolism &amp; Cardiovascular Diseases, 29, 1151-1167. &lt;br&gt;https://doi.org/10.1016/j.numecd.2019.07.012</mixed-citation></ref><ref id="hanspub.38522-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pala, R., Genc, E., Tuzcu, M., et al. (2018) L-Carnitine Sup-plementation Increases Expression of PPAR-Gamma and Glucose Transporters in Skeletal Muscle of Chronically and Acutely Exercised Rats. Cellular and Molecular Biology (Noisy le Grand), 64, 1-6. &lt;br&gt;https://doi.org/10.14715/cmb/2018.64.1.1</mixed-citation></ref></ref-list></back></article>